Supply of leuprorelin acetate (ELIGARD) products by Hospria Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the supply of therapeutic goods within the country, aiming to protect public health by ensuring that such goods are of acceptable quality and safety. The Act establishes a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, through the Therapeutic Goods Administration (TGA). The policy objective of the Act is to safeguard public health by ensuring that therapeutic goods available in Australia meet necessary standards of quality, safety, and efficacy. The 2013 notice regarding the consent for the supply of certain leuprorelin acetate products by Hospria Pty Ltd exemplifies the Act's role in allowing specific therapeutic goods to be supplied under certain conditions, ensuring compliance with regulatory standards while facilitating access to necessary medical treatments.

Scope and Application

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia, ensuring they are safe and of high quality. Under this Act, specific sections such as section 14 and 14A allow for consent to be granted for the supply of therapeutic goods that do not fully conform with certain standards or guidelines, provided specific conditions are met. The Act applies to entities and individuals involved in the supply and distribution of therapeutic goods, encompassing various industries including pharmaceuticals and medical devices. The jurisdictional reach of the Act is national, as it is a Commonwealth Act. However, the Act can be extended or restricted through subordinate instruments such as Therapeutic Goods Orders (TGOs), which provide detailed specifications and standards for different types of therapeutic goods. In this particular instance, the Act facilitates the supply of leuprorelin acetate (ELIGARD) 7.5 mg and 30 mg modified release injections in pre-filled syringes by Hospria Pty Ltd, despite the products not fully conforming to TGO 69 due to outdated address details on the labels. The consent is contingent on specific conditions being met, including the use of submitted labels and adherence to the provided product information and customer contact details.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is a comprehensive piece of legislation that governs the regulation of therapeutic goods in Australia. Sections 14 and 14A of the Act allow the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not conform with certain requirements, provided certain conditions are met. In this instance, the delegate has given consent for the supply of two specific products, leuprorelin acetate (ELIGARD) 7.5 mg modified release injections in pre-filled syringes and leuprorelin acetate (ELIGARD) 30 mg modified release injections in pre-filled syringes, manufactured by Hospria Pty Ltd. The consent is subject to several conditions, including the use of specific labels that include the previous address of the company, the provision of product information as outlined in a letter from the company dated February 18, 2013, and the maintenance of a process for ensuring continuous customer contact with the company. The Therapeutic Goods Act 1989 imposes various obligations and requirements on the parties and entities it governs. In this case, the delegate of the Secretary has imposed specific conditions on the supply of the two products by Hospria Pty Ltd. These conditions include the use of particular labels, the provision of specific product information, and the maintenance of a process for ensuring continuous customer contact. The delegate has also limited the consent to specific batches of the products and has specified that no other changes have been made to the products. These obligations are designed to ensure that the products are supplied in a manner that is safe and effective, and that consumers have access to accurate and up-to-date information about the products. Failure to comply with the conditions of the consent, or with the requirements of the Therapeutic Goods Act 1989 more generally, can result in a range of civil and criminal consequences. Under section 31 of the Act, a person who contravenes certain provisions of the Act, including the requirements for labelling and information, may be guilty of an offence and liable to a penalty. The maximum penalty for an individual is generally five years imprisonment or a fine of up to $330,000, or both. For a body corporate, the maximum penalty is generally a fine of up to $1.65 million. In addition to criminal penalties, civil penalties may also apply, including fines and orders for the recall or seizure of products. In summary, sections 14 and 14A of the Therapeutic Goods Act 1989 allow the delegate of the Secretary to give consent for the supply of therapeutic goods that do not conform with certain requirements, provided specific conditions are met. The delegate has imposed a range of conditions on the supply of two specific products by Hospria Pty Ltd, including the use of particular labels, the provision of specific product information, and the maintenance of a process for ensuring continuous customer contact. Failure to comply with the conditions of the consent, or with the requirements of the Act more generally, can result in criminal and civil penalties, including fines and imprisonment.